Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430617 | 0.87 | ALDH1A1 (0.36) | TGFBR1ALDH1A1HSD17B10KMT2AMGAM | |
| Ammonia Solution, Strong SCHEMBL27426631 | 0.85 | ALDH1A1 (0.34) | ALDH1A1HSD17B10MGAMGAASI | |
| SCHEMBL3432014 | 0.78 | TGFBR1 (0.38) | TGFBR1ALDH1A1MGAMGAASI | |
| SCHEMBL18177629 | 0.77 | ALDH1A1 (0.42) | TGFBR1ALDH1A1TSHRMGAMGAA | |
| SCHEMBL18177632 | 0.77 | ALDH1A1 (0.42) | TGFBR1ALDH1A1TSHRMGAMGAA | |
| SCHEMBL1471267 | 0.75 | TSHR (0.32) | ALDH1A1THRBTSHR | |
| SCHEMBL27840950 | 0.75 | ALDH1A1 (0.40) | ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL3430596 | 0.74 | ALDH1A1 (0.36) | TGFBR1ALDH1A1TSHRMGAMGAA | |
| SCHEMBL4986801 | 0.73 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL41033 | 0.73 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | TGFBR1 1461/4885ALDH1A1 1706/4885THRB 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.